Castle Biosciences Presents Data on DecisionDx®-Melanoma and DecisionDx®-SCC at SDPA Annual Summer Dermatology Conference 2021

Author's Avatar
Jul 22, 2021

Castle Biosciences, Inc. (Nasdaq: CSTL), a dermatologic diagnostics company providing personalized genomic information to inform treatment decisions, today announced data presentations on two of its skin cancer gene expression profile tests at the Society of Dermatology Physician Assistants (SDPA) Annual Summer Dermatology Conference 2021, taking place from July 22-25, 2021.